• Overview
  • Eligibility
  • More info
  • Locations

Procalcitonin Reveals Early Dehiscence In Gastric Surgery: the PREDIGS Study (NCT02756455)

Background. Gastric cancer surgery is associated with high risk for postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Procalcitonin (PCT) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of AL after colorectal surgery than C-reactive protein (CRP) and white blood cell count (WBC). Purpose. Investigators designed a monocentric pilot study to test if PCT might be a sensitive and reliable marker of AL after gastric surgery
  • Other: gastric cancer pts undergoing surgery
    Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
    Ages eligible for Study
    18 Years to 100 Years
    Genders eligible for Study
    Accepts Healthy Volunteers
    Inclusion Criteria:
    • patients undergoing all different kinds of gastric surgery (from partial to total gastrectomy) for cancer, WITH an anastomosis performed
    • elective setting
    Exclusion Criteria:
    • age < 18 years
    • pregnant women
    • patients undergoing gastric surgery for benign disease or other kinds of gastric surgery without an anastomosis being performed

    1 locations

    Italy (1)
    • Sant'Andrea University Hospital
      Rome, Italy, 00189
    Observational Patient Registry
    31 December, 2014
    27 April, 2016
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!